BRIEF published on 11/10/2025 at 07:05, 11 months 8 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
BRIEF published on 11/10/2025 at 07:05, 11 months 8 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
PRESS RELEASE published on 11/10/2025 at 07:00, 11 months 8 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 11 months 12 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 11 months 12 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 11 months 12 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 11 months 13 days ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
BRIEF published on 11/05/2025 at 07:05, 11 months 13 days ago BioVersys présentera ses travaux lors de la conférence annuelle Stifel 2025 sur les soins de santé. New York Conférence Sur Les Soins De Santé BioVersys Développements Cliniques Bactéries Multirésistantes
PRESS RELEASE published on 11/05/2025 at 07:00, 11 months 13 days ago Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york BioVersys AG will present at Stifel 2025 Annual Healthcare Conference in New York, showcasing latest clinical and preclinical developments. Key focus on antibacterial products for MDR bacteria Healthcare Conference BioVersys AG Antibacterial Products MDR Bacteria Stifel 2025
BRIEF published on 11/03/2025 at 07:05, 11 months 15 days ago BioVersys Appoints Dr. Daniel Ritz as Chief Scientific Officer Chief Scientific Officer BioVersys MDR Bacteria Dr. Daniel Ritz Anti-infective
Published on 10/17/2026 at 03:20, 1 day 11 hours ago Battery X Metals Highlights Participation at X Takeover 2026, an Electric Vehicle and Emerging Technology Event Held at Tesla's Gigafactory Texas, Providing Exposure to Industry Perspectives and Technology Developments
Published on 10/17/2026 at 03:15, 1 day 11 hours ago Vanta Closes Second Tranche of Private Placement Financing and Welcomes Launch of First U.S.-Listed Peptide ETF, Highlighting Growing Recognition of Peptide Industry
Published on 10/16/2026 at 23:35, 1 day 14 hours ago Initial Closing of US$3.4 Million Private Placement
Published on 10/16/2026 at 23:30, 1 day 14 hours ago NiobiumX Mining Inc. Announces Retraction of Recent Marketing Materials
Published on 10/16/2026 at 23:00, 1 day 15 hours ago Grid Announces Adoption of Advance Notice By-Law and Provides Shareholder Meeting Update
Published on 10/18/2026 at 14:05, 17 minutes ago UEG launches new Patient Representatives Advisory Board to strengthen patient voice in digestive health
Published on 10/17/2026 at 18:00, 20 hours 23 minutes ago Baader Bank announces extended trading hours 23 hours a day starting Q1/2027
Published on 10/17/2026 at 13:05, 1 day 1 hour ago Luong Quoi Coconut Vietnam to Showcase Vietnamese Coconut Expertise at SIAL Paris 2026
Published on 10/17/2026 at 12:50, 1 day 1 hour ago AGFUND wins international award for excellence in inclusive banking and social impact
Published on 10/16/2026 at 20:08, 1 day 18 hours ago EQS-Adhoc: Rath AG // Rath Group reaches agreement with its key financial creditors on the terms of a transformation agreement and launches a transformation programme
Published on 10/16/2026 at 19:54, 1 day 18 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 30 septembre 2026
Published on 10/16/2026 at 18:48, 1 day 19 hours ago Disclosure of transactions in own shares from October 12 to October 16, 2026
Published on 10/16/2026 at 18:48, 1 day 19 hours ago Déclaration hebdomadaire d'opérations effectuées du 12 au 16 octobre 2026
Published on 10/16/2026 at 18:00, 1 day 20 hours ago KLARSEN : Compte rendu AGO et AGE du 8 octobre 2026
